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Abstract
Background: Fumarate hydratase (HGNC approved gene symbol – FH), also known as fumarase,
is an enzyme of the tricarboxylic acid (TCA) cycle, involved in fundamental cellular energy
production. First described by Zinn et al in 1986, deficiency of FH results in early onset, severe
encephalopathy. In 2002, the Multiple Leiomyoma Consortium identified heterozygous germline
mutations of FH in patients with multiple cutaneous and uterine leiomyomas, (MCUL: OMIM
150800). In some families renal cell cancer also forms a component of the complex and as such has
been described as hereditary leiomyomatosis and renal cell cancer (HLRCC: OMIM 605839). The
identification of FH as a tumor suppressor was an unexpected finding and following the
identification of subunits of succinate dehydrogenase in 2000 and 2001, was only the second
description of the involvement of an enzyme of intermediary metabolism in tumorigenesis.
Description: The FH mutation database is a part of the TCA cycle gene mutation database
(formerly the succinate dehydrogenase gene mutation database) and is based on the Leiden Open
(source) Variation Database (LOVD) system. The variants included in the database were derived
from the published literature and annotated to conform to current mutation nomenclature. The
FH database applies HGVS nomenclature guidelines, and will assist researchers in applying these
guidelines when directly submitting new sequence variants online. Since the first molecular
characterization of an FH mutation by Bourgeron et al in 1994, a series of reports of both FH
deficiency patients and patients with MCUL/HLRRC have described 107 variants, of which 93 are
thought to be pathogenic. The most common type of mutation is missense (57%), followed by
frameshifts & nonsense (27%), and diverse deletions, insertions and duplications. Here we
introduce an online database detailing all reported FH sequence variants.
Conclusion:  The  FH  mutation database strives to systematically unify all current genetic
knowledge of FH variants. We believe that this knowledge will assist clinical geneticists and treating
physicians when advising patients and their families, will provide a rapid and convenient resource
for research scientists, and may eventually assist in gaining novel insights into FH and its related
clinical syndromes.
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Background
Recently two proteins involved in the tricarboxcylic acid
(TCA) cycle have been shown to be tumor suppressors.
Fumarate hydratase (FH) (also known as fumarase) and
succinate dehydrogenase (SDH), which also plays a role
in oxidative phosphorylation, are enzymes involved in
fundamental processes of energy production. Deficiencies
of FH and SDH(A) generally result in early-onset, severe
encephalopathy. The first description of fumarate
hydratase deficiency was in 1986 by Zinn et al [1], fol-
lowed in 1994 by the first molecular characterization of
an FH mutation by Bourgeron et al [2]. In 2002, the Mul-
tiple Leiomyoma Consortium identified FH as the tumor
suppressor gene responsible for MCUL/HLRCC [3].
The identification of these genes as tumor suppressors was
an entirely unexpected finding and demonstrated for the
first time the involvement of proteins of intermediary
metabolism in tumorigenesis. Mutations have been iden-
tified in both the gene encoding fumarate hydratase and
three of the four genes encoding succinate dehydrogenase,
subunits B, C and D (SDHB, -C and -D) [4-6], while no
cancer-related mutations have yet been reported in SDHA.
Germline mutations in FH predispose individuals to mul-
tiple cutaneous leiomyomas, uterine leiomyomas and in
some families renal cell cancer (HLRCC) [7], whereas
mutations in SDH cause hereditary paragangliomas and
pheochromocytomas (HPGL) [8]. Both of these cancer
syndromes are inherited in an autosomal dominant man-
ner. Despite the closely related function of FH and SDH
proteins, the tumor spectra in HPGL and HLRCC show lit-
tle overlap, indicating that although biochemically
related, the mitogenic stimulus leading to tumor forma-
tion must be cell specific.
The principal phenotype of the FH-associated tumor syn-
drome is skin leiomyoma. These are typically sensitive to
cold or abrasion, appear to be more common in women
than men, developing between the second and fourth dec-
ades as intradermal papules or nodules of up to 20 mm in
diameter, with a disseminated or segmental distribution.
Germline FH mutations have been identified in the vast
majority of patients with multiple skin leiomyomas, and
the relatives of probands have often been subsequently
diagnosed with skin leiomyomas, suggesting that many
more cases are currently going unrecognized. Female FH
mutation carriers are also at high risk of early-onset uter-
ine fibroids that frequently require hysterectomy. Certain
FH  mutations have also been associated with uterine
fibroids without skin leiomyomas [9]. Although uterine
fibroids are the most common tumors in women during
their reproductive years, FH mutations do not appear to
play a major role in non-syndromic cases [10]. Although
not always present in the FH syndrome, aggressive renal
cell carcinomas of two unusual types, type II papillary and
collecting duct morphology, also occur in certain families.
Both frequently present with metastatic disease before the
age of fifty and are associated with high mortality. A single
case has also been reported with both papillary and con-
ventional clear cell renal carcinoma, both tumors display-
ing loss of the wild type FH allele and immunostaining
[11]. Recently Merino et al described a distinctive histo-
logical feature of these tumors, a characteristically large
nucleus with a very prominent inclusion-like orangi-
ophilic or eosinophilic nucleolus, surrounded by a clear
halo [12].
Leiomyosarcomas also occur in association with FH
mutations but appear to be rare in FH mutation carriers
although a few cases, predominantly of Finnish origin,
have been described [13,14]. Other reported pathology
associated with FH mutations include cerebral caverno-
mas [15] and Leydig cell tumors [16] and ovarian muci-
nous cystadenoma [17].
A number of biochemical studies have shown that FH-
deficient cells and tumors accumulate both fumarate and
succinate, while SDH-deficient tumors mainly accumu-
late succinate [18-20]. Accumulation of these metabolic
intermediates may affect other biochemical processes in
the cell, and considerable evidence indicates that the inhi-
bition of HIF prolyl hydroxylase leads to the over-expres-
sion of the transcription factor, hypoxia-inducible factor
1α (HIF1α) [21]. HIF1α targets, including vascular
endothelial growth factor (VEGF), erythropoietin (EPO),
and glucose transporter1 (GLUT1), show activation on
accumulation of TCA metabolites, and contribute to an
increase in microvessel density [18,20,22-26]. This phe-
nomenon has been described as "pseudo-hypoxia" and
shows striking similarities with von Hippel-Lindau (VHL)
syndrome [27]. In normoxia, HIF1α is hydroxylated at
critical proline residues by a HIF prolyl hydroxylase, and
targeted for degradation by an E3-ubiquitin ligase com-
plex that includes the VHL protein. In VHL disease, muta-
tions in VHL  inhibit this process and lead to the
stabilization of HIF1α. Phenotypically, both HPGL and
VHL patients may develop pheochromocytomas, and the
clear cell renal carcinomas that are a major feature of VHL
disease [28] have recently been reported in a HPGL family
[29].
Construction and content
The FH mutation database [30] is based on the recently
described Leiden Open (source) Variation Database
(LOVD) system [31] which, under the auspices of the
Human Genome Variation Society, is rapidly becoming
the standard for gene-specific databases. The LOVD sys-
tem was designed to be flexible so that it could be easily
adapted to the needs of a wide range of locus specific data-
bases. Additional flexibility comes from the platform-BMC Medical Genetics 2008, 9:20 http://www.biomedcentral.com/1471-2350/9/20
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independent design and the use of PHP and MySQL open
source software. The design is gene-centered and modular,
and focuses on the collection and display of DNA
sequence variations. The LOVD platform is also easily
extendable to include summary clinical data. In addition,
all database contents may be downloaded in flat text for-
mat and imported into a spreadsheet program for further
analysis. The LOVD database software is now in a new ver-
sion, LOVD2, which has many additional features.
Researchers interested in contributing sequence variants
to the database will be asked to register, (submitters can
access and edit their personal data at any time), after
which they can contribute the variant online. During sub-
mission researchers are asked to provide those data that
are deemed absolutely essential for mutation databases by
the Human Genome Organization Mutation Database
Initiative. These include a patient ID, an exact molecular
description of the variant (DNA-level), and details about
the source of the material and detection method used.
Newly submitted variants are given a unique identifier, as
recommended by Claustres et al [32]. After the curator's
approval the new variant is added to the database and all
connected web pages are updated instantly. Currently
(Jan, 2008) all database content is derived from pub-
lished, peer-reviewed literature. We anticipate that directly
submitted content will become an increasing proportion
in the future. As the submitted data are in the form of a
submitter deduced mutation description, the curators can
only check the feasibility and consistency of the descrip-
tion and not any original data.
DNA variation in populations is generally benign and as
such should be termed a 'variant' or 'SNP'. The term
'mutation' is reserved for cases were there is a reasonable
suspicion that the variant is deleterious. DNA variants
submitted to the FH  database should be described in
accordance with the recommendations of the Human
Genome Variation Society (HGVS), update August 2004,
and it is strongly recommended that authors consult the
most up-to-date nomenclature guidelines, which can be
found online at the HGVS website. Unfortunately the
mutation nomenclature currently used in the field of FH
research is rarely in agreement with HGVS guidelines.
Reports contain a variety of annotations, and many are
based on the annotation of the cytosolic protein, the func-
tion of which is currently poorly defined [33]. One of the
aims of the HGVS is to establish a consistent nomencla-
ture across all human genes. The description of FH protein
variants based on the cytosolic protein is often accompa-
nied by the use of a truncated transcript to describe cDNA
variants. Other authors use the cytosolic protein number-
ing system, while applying the full-length coding tran-
script to describe cDNA variants. This results in the loss of
the simple approximation of 3 to 1 between the number-
ing. The HGVS-recommended cDNA numbering starts
from the first ATG of the full coding sequence. Protein ref-
erence sequences should represent the primary translation
product, not a processed mature protein, and thus include
any signal peptide sequences Currently many variants are
present in the literature under several titles, and the cor-
rect identification of intron variants is especially problem-
atic. No reliable overview of known FH variation can be
achieved without a consistent nomenclature, which
includes the appropriate numbering systems at both the
DNA and protein level. We now recommend that all
authors implement the recommendations of the HGVS
when describing future FH variants.
The FH mutation database will accept all variants and if
necessary assist in assigning the correct nomenclature. In
light of the inconsistency of the recent FH  mutation
nomenclature, variants have been reassigned, where nec-
essary, and an extra column has been generated clearly
stating the originally reported description(s) of the muta-
tion at the protein level, and where equivocal also at the
cDNA level. Inclusion of sequence variants in the FH
mutation database does not imply that there is convincing
evidence for pathogenicity. Please refer to the disclaimer
on the website.
Within the FH database, all variants that disrupt the read-
ing frame, affect highly conserved residues (conserved by
sequence alignment in at least Saccharomyces cerevisiae) or
disrupt the consensus donor or acceptor splice sites (GT-
AG), and are not found in healthy controls, should be sus-
pected as potentially pathogenic. Non-conserved mis-
sense variants and potential splice site mutations that do
not disrupt the consensus splice sites, are considered to be
SNPs or rare variants of uncertain significance. Ideally,
several lines of evidence should support publications
which present mutations as "pathogenic", including
screening DNA from a panel of 50–200 healthy individu-
als, describing the nature of the amino acid substitution
(conservative/non-conservative) and the significance of
the position in the protein (evolutionarily conservation or
known functional domain). It is important to note
whether the mutation has previously been reported, if it
has been found in several families, and if it segregates with
the disease within the family.
Many FH variants have been analysed for effects on enzy-
matic function, and this data has, in many cases, allowed
the classification of missense variants as pathogenic. In
addition a SIFT (Sorting Intolerant From Tolerant) analy-
sis [34] of missense FH variants has been included. A high
score (above 0.05) indicates that an amino acid is poorly
conserved (alignment of 337 Uniprot proteins), indicat-
ing caution in assignment of function to the variant.BMC Medical Genetics 2008, 9:20 http://www.biomedcentral.com/1471-2350/9/20
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However none of these factors can be seen as definitive
and each variant must be considered on its merits. Unfor-
tunately, most mutations are currently reported without
this accompanying analysis, and many have been identi-
fied in a single case or family. Thus caution should be
exercised when attempting to derive clinically relevant
information from the database, and users must carefully
weigh all the evidence in the database and any additional
data.
The FH gene is very highly conserved, showing 67% pro-
tein identity between humans and S. cerevisiae with the
few coding SNPs described in dbSNP present in the Hap-
Map population as very rare alleles (the minor allele being
undetected). Thus, current knowledge suggests that most
missense changes will be pathogenic. Polymorphisms,
including intron variants, synonymous (silent) variants,
nonsynonymous missense variants found in a healthy
control panel and potential non-consensus splice site
mutations but without evidence for transcript rearrange-
ments are included in the database as such unless accom-
panied by clear evidence of pathogenic potential.
An abbreviated description of the FH related syndrome is
given under "disease". Refer to the database notes for an
explanation of these abbreviations. Further information
can be found under "remarks", including the country of
origin of the patient or study, together with other details
such as the number of healthy controls tested for the var-
iant, and any other supporting evidence.
Utility
The FH mutation database describes mutations exon by
exon; giving a complete overview of all reported or
directly submitted mutations in a single table. This over-
view permits the swift appraisal of the status of any new
variant. The FH mutation database summary page lists
general gene and database information and provides
access to the tables containing the allelic variant informa-
tion and several search options (Fig 1). In addition, the
complete contents of the public database can be down-
loaded here and imported into a spreadsheet program for
further analysis.
The variant tables contain the sequence variants ordered
by position, relative to the cDNA reference sequence (Fig
2). Tables describing both unique variants and all
reported variants can be selected. Using the sort option in
the column heading, variants can be re-ordered as
required. An up-to-date and fully referenced overview of
FH mutations will be especially useful to clinical geneti-
cists, research scientists, and physicians involved in the
care and treatment of patients with HLRCC or congenital
fumarase deficiency.
The FH mutation database introductory page Figure 1
The FH mutation database introductory page. In addition to summary tables, various search options are also available.BMC Medical Genetics 2008, 9:20 http://www.biomedcentral.com/1471-2350/9/20
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Discussion
The FH database includes (as of Jan, 2008) 107 variants of
which 93 are thought to be pathogenic and 14 may be
non-functional intron variants. The most common types
of mutations at the protein level are missense (57%),
frameshifts and nonsense (27%), with the remainder
composed of deletions, insertions and duplications (Fig
3). No mutation has yet been identified in exon 1 (often
described as exon 0), and few large deletions have been
reported but this probably reflects limited effort in this
direction to date. The missense mutations are concen-
trated in several central exons of the gene, particularly 4,
5, 7 and 8. Unsurprisingly the most conserved exon is 7,
followed by exon 4. It can also be noticed that the mis-
sense mutations of exon 5 cluster in the proximal and dis-
tal regions of the exon, which are both highly conserved
(Fig 4).
That conservation is not always a good predictor of func-
tion is seen with Lys467Arg (K424R) missense variant.
This amino acid is relatively poorly conserved, present in
E. coli, but variable in many other species. The SIFT score
is 0.17, indicating that this is a tolerated variant, and
should not affect protein function. Other species variants
include Asn, Ala, Met, and Glu, all of which are also pre-
dicted by SIFT analysis to be tolerated changes. However,
Ylisaukko-oja et al recently demonstrated that this variant
has less than half the activity of the wt variant [13]. Con-
text may also be important for the function of a variant, a
case in point being Glu362Gln (Glu319Gln), the very first
FH mutation, described by Bourgeron in 1994 [2]. Two
siblings with profound fumarase deficiency were found to
be homozygous for this mutation, showing only residual
fumarase activity of less than 0.5% of controls. The
glutamine (Gln) variant residue is the only change pre-
dicted by SIFT analysis to be tolerated. It can be speculated
that any other change in this highly conserved distal
region of exon 7 would have resulted in such a complete
loss of fumarase activity as to be incompatible with life.
Renal cell cancer (RCC) associated mutations occur
throughout the gene with the exception of exons 1 and 6,
though there are perhaps fewer RCC-associated mutations
in exon 7 than one might expect (Fig 4). The Arg233His
(R190H) mutation is the most commonly described FH
variant, so it is unsurprising this residue should be
mutated in a few cases of RCC. However, arginine 233 is
also independently affected, with less common variants
(Arg233Cys, Arg233Leu) and all changes have been asso-
ciated with RCC. This residue resides in the A-site which
may be the main catalytically active site [35]. Previously
Alam et al [36] speculated that truncating mutations may
A partial overview of the FH unique allelic variants table Figure 2
A partial overview of the FH unique allelic variants table.BMC Medical Genetics 2008, 9:20 http://www.biomedcentral.com/1471-2350/9/20
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be over-represented in renal cancer families. Within the
current database, truncating and missense mutations are
equally represented (11 vs. 11) in renal cell cancer
patients (Fig 4). This still represents relatively more trun-
cating mutations associated with RCC than in the overall
database, but the current trend seems to indicate that the
initial imbalance was an artefact of the limited numbers
of variants then known. Whether truncating mutations are
more penetrant, leading to more cases of RCC than the
missense variants, is currently unclear from the published
clinical data.
A number of FH missense mutations have been reported
to reduce FH activity below that seen for truncating muta-
tions, indicating a dominant negative action [37]. A sec-
ond study failed to confirm differential activities of
truncating and missense mutations on FH enzyme activity
in lymphoblastoid cell lines from HLRCC patients [38].
However, Lorenzato et al recently formally demonstrated
the dominant negative action of the Arg233His (R190H)
mutation [39]. For a more complete functional analysis of
FH missense mutations see Alam et al [36,37].
As described above, patients with mutations of FH display
a range of pathologies, the most profound, FH deficiency,
related to mutation of both FH alleles. We have previously
noted [3,37] the tendency of FH deficiency-associated
mutations to occur later in the gene (Fig 4) and to be less
likely to include mutations leading to complete loss of
protein function. While several cases of FH deficiency
have been reported together with truncating mutations,
the other affected allele tended to carry a missense muta-
tion. The only case carrying two profound mutations was
reported by Coughlin et al [40]. This patient (F1430) had
only 2% residual FH enzyme activity, but did not show
the most serious of the known clinical manifestations.
Even the mutations in this patient may have been attenu-
ated by the fact that while one allele was affected by a 74
bp deletion in exon 2, the other truncating mutation
occurred very late in the protein at the end of exon 10,
leading to the loss of the last 10 amino acid residues.
These data suggest that some residual enzyme activity is
required if an embryo is to develop to term.
Conclusion
Here we present an online database of FH gene variants
that provides the only complete and up-to-date overview
of all reported disease-related mutations.
Clearly, considering the geographical distribution of the
studies to date, only a fraction of all FH mutations associ-
ated with MCUL/HLRCC have yet been identified. While
no unequivocal genotype-phenotype correlations associ-
ated with certain types of mutations or location in the
gene have emerged so far [37], increasing knowledge of
FH mutations may yet provide insight into sub-pheno-
Summary of the relative frequency of FH variant types Figure 3
Summary of the relative frequency of FH variant types. Small deletions include all except whole exon deletions; large deletions 
include whole exon to whole gene deletions.
Splicesite 6%
Small Deletion 
4%
Duplication 2%
Large Deletion 
4%
Frameshift & 
Nonsense 27%
Missense 57%BMC Medical Genetics 2008, 9:20 http://www.biomedcentral.com/1471-2350/9/20
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types or FH protein function. Importantly, every FH muta-
tion found in an MCUL/HLRCC patient increases
confidence in the pathogenic role of that variant, improv-
ing the accuracy of clinical genetic counselling. Equally it
remains extremely important to test missense variants in
sufficient, ethnically matched, healthy controls to aid in
identifying SNPs in the coding sequence, which may cur-
rently be incorrectly classified.
We hope that the FH mutation database, which strives to
systematically unify all current genetic knowledge of FH
variants, will increase the confidence of clinical geneticists
and treating physicians when advising patients and their
families, will provide a convenient resource for research
scientists, and may eventually assist in gaining novel
insights into FH and its related clinical syndromes.
Availability and requirements
The  FH  mutation database; http://chromium.liacs.nl/
LOVD2/SDH/home.php?select_db=FH is freely accessible
and all researchers may submit new sequence variants
online (after registration – to collect contact information
for reference purposes and clarification of submitted
details, as well as to assign a login name and password).
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Overview of the exon distribution of FH missense, renal cell cancer associated and exclusively FH deficiency related mutations Figure 4
Overview of the exon distribution of FH missense, renal cell cancer associated and exclusively FH deficiency related mutations. 
Mutations in red have been identified in cases of renal cell cancer of either type II papillary or collecting duct morphology. Var-
iants in yellow have (as yet) been found exclusively in cases of FH deficiency. The accompanying table lists the numbers of mis-
sense variants per exon. (*These mutations are distinct at the DNA level).
8 1 7 9 10 6 5 4 2 3
p.Arg51Glu
p.Asn78fs
c.267+1G>C
p.Arg101Pro
p.Asn107Thr
p.Ala117Pro
p.Leu132Ser
p.His135Arg
p.Gln142Lys
p.Ser145X
p.Ser158Ile
p.Arg160Gly
p.Pro174Arg
p.His180Arg
p.Gln185Arg
p.Lys230Arg
p.Arg233Cys
p.Arg233Leu
p.Arg233His
p.Ala239Thr
p.Ser187Leu
p.Asn188Ser
p.Pro192Leu
p.Met195Thr
p.His196Arg
p.Glu224fs
p.Ile229Thr
p.Ala274Thr
p.Gly282Val
p.Ala308Thr
p.Asn310Tyr
p.Phe312Cys
p.His318Tyr
p.His318Leu
p.Val322Asp
p.Thr330Pro
p.Glu355Lys
p.His402Cys
p.Asn361Lys
p.Glu362Gln
p.Ser365Gly
p.Cys333Tyr
p.Asn340Lys
p.Ser366Asn
p.Pro369Ser
p.Asn373Ser
p.Gln376Pro
p.Glu378fs
p.Ala385Asp
p.Val394Leu
p.Gly397Arg
p.Tyr465Cys
p.Lys467Arg
p.Gly490fs
p.Leu507Pro
RCC
FH deficiency only
Missense
p.Leu335Pro
p.Arg101X
p.Ile81fs
p.Arg343X
p.Ser419Pro
p.Asp425Val
p.Thr431fs*
p.Gln439Pro
p.Met454Ile
p.Thr431fs*
10 9 8 7 6 5 4 3 2 1 Exon
3 4 6 16 2 11 8 3 1 0 MissenseBMC Medical Genetics 2008, 9:20 http://www.biomedcentral.com/1471-2350/9/20
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